Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.

Decker, Thomas

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. [electronic resource] - BMC cancer Apr 2020 - 286 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial

1471-2407

10.1186/s12885-020-06747-y doi


Aged
Aged, 80 and over
Androstadienes--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab--administration & dosage
Breast Neoplasms--drug therapy
Capecitabine--administration & dosage
Cross-Over Studies
Estrogen Receptor alpha--metabolism
Everolimus--administration & dosage
Female
Humans
Middle Aged
Patient Preference--statistics & numerical data
Prognosis
Quality of Life
Receptor, ErbB-2--metabolism
Receptors, Progesterone--metabolism
Survival Rate
Treatment Outcome